RxDoctor Payments Data

Dana Short, NP

Nurse Practitioner · Taylorsville, NCNPI 1962817528

Payments from drug & device makers

$948in general payments, 2019–2025

Across 39 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$237
  • AstraZeneca$144
  • Novo Nordisk$93
  • Lilly USA, LLC$72
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58
  • Dexcom, Inc.$58
  • plus $286 from 13 others

What the payments were for

  • Food & beverage$948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$948 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$7,036
Medicare patients
94
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$60,448
OzempicSemaglutide50$57,176
VraylarCariprazine Hcl21$54,499
MounjaroTirzepatide15$22,881
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$20,112
EliquisApixaban27$18,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,362
VascepaIcosapent Ethyl15$9,124
Tresiba Flextouch U-100Insulin Degludec11$5,629
Albuterol Sulfate HfaAlbuterol Sulfate73$2,020
Gabapentin103$1,977
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$1,443
Omeprazole61$1,283
Ventolin HfaAlbuterol Sulfate23$1,251
Atorvastatin Calcium147$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$57,17650 claims
AbbVieVraylar$49$54,49921 claims
Lilly USA, LLCMounjaro$72$22,88115 claims
AstraZenecaBreztri Aerosphere$144$20,11223 claims
PfizerEliquis$21$18,57927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Taylorsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →